Key Takeaways
- Revenue momentum intact, margin dip is accounting noise: Revenue growth continued across PI, API and contrast media platforms, but reported gross margin fell to 48.5% from 55% QoQ. Management attributes 4.4 pp of the decline to a ₹75 crore finished goods inventory drawdown that released prior-quarter overheads into the P&L, calling the combined Q4+Q1 gross margin of 53% the true run rate.
- Contrast media is in a trough, with a path back: Revenue has declined from ₹500 cr (FY23) to a ~₹97 cr quarterly run rate in Q1 FY26, driven by customer facility changes and phasing. Management sees a good probability of returning to FY23 levels, which would become a new base.
- The CDMO pipeline is deepening fast: The company is tracking ~20 new opportunities, ~6 in late Phase III or commercial phase, and has 45 peptide fragments ready for near-immediate commercialization based on customer interest. A new Hyderabad R&D center and a multipurpose GMP plant at Mahad (H2 FY27) will expand the chemistry toolkit into peptides, GLP-1 intermediates and biocatalysis.
- Capacity build-out is aggressive and multi-year: Unit-3 Mahad (₹300 cr, H2 FY26) adds continuous processing and backward integration; a much larger land parcel is being finalized for a three-phase CDMO campus; management will shortly announce a bigger capex outlay and targets asset turns of 2.5–3x over five years.
- What to watch next quarter: Whether the iodinated intermediate launch in Q2 delivers the promised realization uplift, the pace of contrast media volume recovery as client offtake ramps, and any concrete announcement on the new land parcel and associated capex plan.
The Margin Story: Inventory Timing, Not Deterioration
- The ₹75 crore inventory release: Finished goods inventory declined by ₹75 crore QoQ, releasing overheads that had been absorbed into inventory in Q4 directly into Q1 cost of goods sold. This single item accounted for 4.4 pp of the 6.5 pp gross margin decline.
- Product mix added pressure: The remaining 2.1 pp decline came from a higher contribution of PI and API segments relative to the higher-margin "others" segment.
- The combined-quarter math: Management states the blended gross margin across Q4 and Q1 is 53%, and that this level is sustainable on the current portfolio mix. Had finished goods inventory stayed flat QoQ, the reported margin would have been close to that figure.
- New launches could shift the number: Management flagged that launches slated for Q2 and Q3 could change the gross margin profile, but declined to give forward guidance on a range or the specific impact of the iodinated ABA HCL launch.
Ganesh Karuppannan: "I would actually say this is more an accounting, the way Sanjay put it across. When the inventory gets released, this overhead absorption happens. I think had we maintained a similar finished goods level like last quarter; you would not have seen this impact."
Contrast Media: The Trough and the Recovery Bet
- The decline: Contrast media revenue fell from ₹500 cr (FY23) to ₹480 cr (FY24) to ₹400 cr (FY25), with Q1 FY26 at a ₹97 cr quarterly run rate, well below historical averages. The drop is attributed to customer facility changes and order phasing, not demand destruction.
- The recovery path: Commercial volumes from new molecules launched in Q4 FY25 have stabilized, and sequential growth is expected in H2 as client offtake ramps up. A production plan is in place for Q2 and Q3 to return to original output levels.
- The FY23 base-case aspiration: Management sees a good probability of returning to the ₹500 cr level, which would then serve as a new base. The iodinated intermediate launch in Q2 and the iodinated AB HCL backward integration launch in H2 are key enablers.
- Longer-term capacity: The new land parcel's first phase dedicates two of four blocks to contrast media, signaling confidence in demand beyond the recovery. Newer contrast agent intermediates are already in lab quantities.
Ganesh Karuppannan: "If we look at all the three together, there is a good probability we should actually get back to the 23 levels. I think that is our aspiration. So, that's what we are working on. So, this would actually become a new base for us."
PI & API: The Growth Engine Scaling Up
- Cardiovascular intermediate: The molecule is doing extremely well in US, Europe and ROW markets, with consistent growth over several quarters. Realizations have remained stable and margins are intact at the current cost structure. Esperion's lifecycle management with newer combination products provides additional tailwind.
- Iodinated intermediate launch: Capacity is ready and supply begins in Q2. Management states the net realization per kg improves significantly with this launch, calling it a "fairly good needle mover" for the growth journey, though it declined to disclose volume or KL capacity.
- PI addressable market: The PI opportunity is described as much larger than contrast media, with China-plus-one tailwinds driving RFPs. Management cautioned against extrapolating quarterly run rates in a CDMO business, where a quarter is not a good indication of trajectory.
- Pharma intermediates pipeline: New opportunities are being tracked, and additional launches are expected in H2. The multipurpose plant at Mahad (H2 FY27) will cater to pharma intermediate and peptide fragment requirements, with smaller needs served from the existing Unit-2 multipurpose plant until then.
Shiven Arora: "In terms of what I can share right now, the net realization per kg improves significantly with this launch, we won't be able to disclose the volume or KL capacity. But from a criticality standpoint, and our growth journey, this is a fairly good needle mover."
Capacity Build-Out: The Multi-Year Expansion Thesis
- Unit-3 Mahad (H2 FY26): Designed for continuous processing, with backward integration for the CMI segment via a flow-synthesis-based KSM plant. Capex has been revised from ₹250 cr to ~₹300 cr due to high automation and versatility. Balance capex of ₹200 cr to be incurred up to FY27.
- Multipurpose GMP plant at Mahad (H2 FY27): A ~30-reactor plant with capability from a few kilos to multi-tons, targeting pharma intermediates and peptide fragments.
- New land parcel: A much larger piece of land is being finalized for a three-phase, globally competitive CDMO campus. Phase one includes four blocks: two for contrast media, one for a successive-generation high-intensity sweetener, and one multipurpose block. An announcement is expected shortly.
- R&D center at Hyderabad: ₹40 cr committed, focused on peptides, GLP-1 intermediates, and biocatalysis with immobilized catalysts. One lab will be dedicated to peptide synthesis.
- Peptide readiness now, capacity later: The company has developed 45 peptide fragments that are ready for near-immediate commercialization based on customer interest. Larger-scale peptide capacity will be included in the new land parcel.
- Asset turn ambition: Over the next five years, management targets company-level asset turns of 2.5 to 3x, though it declined to break this out by product category, citing fungible capacities.
VK Singh: "We took that, but then we felt that that was subscale because now we have spotted and in the process of finalizing a much, much larger piece of land. Therefore, it was logical for us to surrender this in view of the much larger parcel of land that we would be acquiring very shortly."
Sweeteners & Other Segments
- High-intensity sweeteners: Volumes remain steady and ASPs are stabilizing after a soft FY25. The value-added variant strategy is intact, and the business is well-positioned with almost all FMCG clients.
- Successive-generation sweetener: Planned for phase one of the new land parcel, though no timeline was given.
- Other operational items: Employee costs and utility overheads remain well-controlled. A ₹2.7 cr one-time GST demand hit EBITDA. Forex gains were lower due to US dollar depreciation in Q1. No major raw material price changes were reported.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin sustainability | 53% on current portfolio mix | Coming quarters |
| Iodinated intermediate supply start | Capacity ready; supply begins | Q2 FY26 |
| Iodinated AB HCL launch | Backward integration launch | H2 FY26 |
| Unit-3 Mahad commissioning | Continuous processing and CMI backward integration on stream | H2 FY26 |
| Additional PI/API launches | New launches in pharma intermediates and API | H2 FY26 |
| Contrast media sequential growth | Client offtake ramp-up drives H2 growth | H2 FY26 |
| Multipurpose GMP plant at Mahad | ~30-reactor plant for pharma intermediates and peptide fragments | H2 FY27 |
| Balance Unit-3 capex | ₹200 cr to be incurred | Up to FY27 |
| Iodinated molecule full-year impact | Full-year contribution visible | FY27 |
| NCE molecule growth | Growth expected | FY27-28 |
| New contrast media opportunities | Additional capacities for contrast media | FY28-29 |
| Capacity addition | 1,000 KL to be added, backed by client lock-ins | Next 2-3 years |
| Asset turn target | Company-level asset turns of 2.5–3x | Next 5 years |
| New land parcel announcement | Much larger parcel being finalized | Shortly |
| Larger capex outlay announcement | Bigger outlay for future expansion to be communicated | Shortly |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue from operations | ₹354.8 cr, up 4% sequentially and 118% YoY |
| EBITDA | ₹120 cr, margin 34.1%, down 7% sequentially, up 173% YoY |
| PAT | ₹91.2 cr, net margin 25.7%, down from Q4, up 148% YoY |
| Gross margin | 48.5%, down 6.5 ppt from 55% in Q4; 4.4 ppt of decline from inventory drawdown, 2.1 ppt from product mix |
| PI and API segment revenue growth | 8.2% QoQ |
| Artificial sweetener segment revenue growth | 17.4% QoQ |
| Contrast media segment revenue | ₹97 cr, down 3.9% QoQ |
| Cash and treasury instruments | ₹270 cr |
| CAPEX incurred in Q1 | ₹28 cr |
| Capacity utilization (company level) | ~75% |
| Capacity utilization (Unit-2 Ambernath, PI segment block) | 60% |
| Active RFPs | ~20, up from 11 or 12 last year; 6 in late phase III or commercial |
| Contrast media end formulation market size | $6.7 bn, projected to reach $10 bn in the next few years |
| GST demand (one-time impact on EBITDA) | ₹2.7 cr, impacted EBITDA by ~0.7% |